Explore more price target data and ratings for Natera, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Natera, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a…
Q2 2026 saw 38% revenue growth to $753M, with test volumes and gross margin both rising year-over-year. Oncology and women's health segments drove strong performance, and 2026 revenue guidance was raised by $100M at the midpoint.Original document: Natera, Inc. [NTRA] Slides Release — Aug. 6 2026Thi…
Genetic testing company Natera NASDAQ:NTRA will be announcing earnings results this Thursday afternoon. Here’s what investors should know.Natera beat analysts’ revenue expectations last quarter, reporting revenues of $696.6 million, up 38.8% year on year. It was a satisfactory quarter for the compa…
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of results from a prospective, multicenter study in Merkel cell carcinoma (MCC) published in JAMA Dermatology. The study evaluated the Signatera test against the Merkel cell polyoma…
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today highlighted the impact of a final local coverage determination (LCD) for molecular testing for solid organ allograft rejection: L40060.The LCD strengthens coverage for Prospera in the surveillance settings…
(16:44 GMT) Natera Price Target Raised to $300.00/Share From $270.00 by Evercore ISI Group
Natera NTRA recently announced a partnership with Aveta Biomics to support AVTA 30-01, a global Phase 3 registrational trial of its oral immunotherapy, APG-157, in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Natera’s Signatera test will be integrated into the AV…
(14:13 GMT) Natera Price Target Raised to $290.00/Share From $270.00 by Guggenheim
By Sahil PandeyGenetic testing firm Natera NASDAQ:NTRA and cancer drug developer Aveta Biomics said on Monday they have partnered on a late-stage study of an experimental therapy for head and neck cancer, in a bid to improve how patients' response to treatment is monitored.Shares of Natera were up…
WASHINGTON (dpa-AFX) - Natera, Inc. (NTRA), a clinical genetic testing company, and Aveta Biomics, Inc., an immuno-oncology company, on Monday announced a partnership to support AVTA 30-01, Aveta's Phase 3 trial evaluating its immunotherapy candidate APG-157 in patients with locally advanced head a…
Genetic testing firm Natera NASDAQ:NTRA and cancer drug developer Aveta Biomics said on Monday they have partnered on a late-stage study of an experimental therapy for head and neck cancer, in a bid to improve how patients' response to treatment is monitored.Here are some details:
